Equities

Tissue Regenix Group PLC

Tissue Regenix Group PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)62.00
  • Today's Change0.00 / 0.00%
  • Shares traded11.85k
  • 1 Year change+12.73%
  • Beta2.2847
Data delayed at least 20 minutes, as of Nov 13 2024 15:09 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tissue Regenix Group plc is a medical device company in regenerative medicine. The principal activity of the Company is the exploitation of platform technologies in the field of bone graft substitutes and soft tissue. It is focused on the development of regenerative products utilizing its two platform technologies, dCELL, addressing soft tissue needs, and BioRinse, providing sterile bone allografts. Its divisions include dCELL, BioRinse and GBM-V. The Company's patented decellularization technology (dCELL) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Its proprietary BioRinse technology platform is primarily utilized to provide sterile tissue prepared in a manner to minimize the negative effects of processing. GBM-V produces tissue preparations for ophthalmology, primarily cornea, using conventional, classical methods.

  • Revenue in GBP (TTM)24.94m
  • Net income in GBP-863.73k
  • Incorporated2006
  • Employees76.00
  • Location
    Tissue Regenix Group PLCUnit 3Phoenix Court, Lotherton Way, GarforthLEEDS LS25 2GYUnited KingdomGBR
  • Phone+44 190 456 7609
  • Fax+44 190 438 0517
  • Websitehttps://www.tissueregenix.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Genedrive PLC272.00k-5.00m13.31m43.00--2.49--48.92-0.0407-0.04070.00220.00980.0658--1.606,325.58-120.84-97.55-197.86-128.51-----1,837.50-797.031.36-7.490.0789--12.24-50.95-10.16--16.72--
Abingdon Health PLC6.14m-1.27m15.01m85.00--4.37--2.45-0.0104-0.01040.04840.01781.106.384.2872,176.47-22.70-52.46-35.04-85.0059.9735.93-20.72-121.701.70-63.000.3181--51.6721.9263.36---15.69--
Inspiration Healthcare Group PLC34.30m-9.76m15.47m224.00--0.5531--0.4509-0.1421-0.14210.49850.31190.65571.544.11153,120.50-18.661.04-22.641.2844.8847.61-28.461.161.15-1.750.3472---8.7419.43-2,318.38--32.41--
Belluscura PLC1.42m-14.59m17.85m35.00--1.15--12.61-0.1017-0.10170.00960.09180.07420.39540.395640,456.66-76.44-49.84-84.73-54.78-33.28-66.07-1,030.73-1,277.342.09-10.150.00---40.9627.44-127.13--41.32--
Polarean Imaging PLC1.47m-6.70m18.58m29.00--1.50--12.68-0.0252-0.02520.00550.01030.10750.51091.8450,545.88-49.18-61.45-58.32-69.1744.7850.68-457.39-810.925.24--0.0093---13.75-18.2414.53--64.51--
Renalytix PLC2.67m-36.26m26.95m80.00--0.5182--10.09-0.4439-0.44390.03250.15440.06462.884.0633,370.67-87.73-58.25-120.00-67.0320.60---1,358.30-1,904.791.71-9.620.397--14.58--18.52------
ANGLE plc2.02m-18.03m31.46m150.00--1.28--15.54-0.0684-0.06840.00770.0760.05530.31171.2113,493.33-49.30---55.77--69.07---890.91--4.80--0.1469--109.99--7.17------
Ondine Biomedical Inc919.30k-8.03m32.77m43.00--2,092.06--35.65-0.0365-0.03650.00420.000040.28590.54979.93---249.74---597.99--60.04---873.56--0.4828--0.9487--88.56--25.60------
Tissue Regenix Group PLC24.94m-863.73k44.69m76.00--1.901,499.081.79-0.0123-0.01230.35360.33010.70611.336.41328,220.30-2.17-13.45-2.43-14.7849.4845.90-3.08-28.801.470.37160.263--20.5013.7536.44--9.78--
Inspecs Group PLC195.14m-4.11m62.53m1.67k--0.61347.350.3204-0.0404-0.04041.921.000.86672.317.65116,640.80-1.82-1.48-2.62-2.1551.4648.50-2.10-1.970.86960.64410.377--1.1636.4584.22--51.04--
SDI Group PLC65.85m4.23m63.25m503.0015.051.397.680.96060.04020.04020.62560.43440.7930.9895.34130,906.605.127.856.1110.0130.8464.066.469.481.354.850.3210.00-2.5630.469.3017.2212.08--
Creo Medical Group PLC30.30m-22.40m75.22m278.00--1.39--2.48-0.0629-0.06290.08520.13110.38351.853.33105,574.90-28.35-26.07-32.89-30.9449.5047.58-73.93-118.242.38--0.2305--13.36--19.44------
EKF Diagnostics Holdings PLC50.95m4.78m121.60m309.0025.481.7712.172.390.01050.01050.11230.15160.63073.016.99160,728.706.345.207.356.1348.0550.0410.057.913.081,703.500.0175113.68-21.054.34123.28-25.3030.37--
Data as of Nov 13 2024. Currency figures normalised to Tissue Regenix Group PLC's reporting currency: UK Pound GBX

Institutional shareholders

45.94%Per cent of shares held by top holders
HolderShares% Held
Harwood Capital LLPas of 29 Feb 202410.62m14.87%
Lombard Odier Asset Management (Europe) Ltd.as of 05 Nov 20248.98m12.58%
UBS Asset Management (UK) Ltd.as of 01 Oct 20244.86m6.80%
Janus Henderson Investors UK Ltd.as of 01 Oct 20243.66m5.12%
Hargreaves Lansdown Asset Management Ltd.as of 01 Oct 20242.29m3.21%
IG Markets Ltd.as of 01 Oct 2024860.00k1.21%
Close Asset Management Ltd.as of 01 Oct 2024455.00k0.64%
J. M. Finn & Co. Ltd.as of 01 Oct 2024394.00k0.55%
HSBC Global Asset Management (UK) Ltd.as of 01 Oct 2024390.00k0.55%
KBC Asset Management NVas of 01 Oct 2024306.00k0.43%
More ▼
Data from 30 Jun 2024 - 07 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.